Ainos, Inc. (AIMD) Stock

Ainos, Inc. (AIMD) is a Technology stock trading at $1.92 (as of 2026-06-18), with a market capitalization of $6.12M and a trailing P/E of -0.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ainos, Inc. develops medical technologies for point-of-care testing and treatment approaches. Its offerings include COVID-19 antigen rapid test kits and a cloud-based test management application, COVID-19 nucleic acid testing, volatile organic compound point-of-care testing, and oral interferon alpha formulations, with additional synthetic RNA technology activities in Taiwan.

Valuation — source: SEC EDGAR (first-party)
Price	$1.92
Market Cap	$6.12M
P/E Ratio	-0.5
EV / EBITDA	-1.6
Price / Book	2.86
Price / Sales	899.00
DCF Value (model)	$-10.84
DCF Upside vs Price	-666.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$124157.00
Net Margin	-11897.0%
Return on Equity	-245.0%
Current Ratio	0.55
Revenue Growth (YoY)	-99.8%
EPS Growth (YoY)	95.2%
FCF Growth (YoY)	-21.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-6.10 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.5
Sector P/E (Technology)	32.6
Industry P/E (Computers)	31.3
vs Sector	-101.6%
vs Industry	-101.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RENAISSANCE TECHNOLOGIES LLC ($108732.00)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Computers
CEO	Chun-Hsien Tsai
Employees	44
Country	US
IPO Date	2021-01-08

Related Companies (Business model: Consumer Hardware (incl. ecosystem services); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.